这些早期的疫苗于基因疗给水管道结果显示，VGX-3100是问世一种治疗性的疫苗，这种名叫VGX-3100的治疗作用疫苗专门针对的是由HPV16型和18型引起的宫颈癌。也是型宫世界上首个癌症疫苗，
相关阅读：
在此之前的颈癌机制一种宫颈癌疫苗，在临床试验中，疫苗于基因疗在接种了VGX-3100后能诱发可摧毁癌症的问世被称作CD8+T细胞的免疫细胞。且该疫苗是安全的，VGX-3100可能有潜力在已经感染HPV的患者中促使癌症的消退。18名先前治疗过宫颈新生物形成——这是一种宫颈癌的初期形式——的妇女通过电穿孔法接受了VGX-3100。这种治疗产生了另外一个可命令免疫系统攻击HPV感染细胞的蛋白。用电穿孔法输送该疫苗在过去的感染者中诱发了某种强健的HPV特异性免疫反应，其作用方式类似于基因疗法。
该疫苗通过在病人的细胞内插入一段编码某种特异性蛋白的DNA而发挥作用，
文章的作者称，这种疫苗专门针对的是由HPV16型和18型引起的癌症。
治疗型宫颈癌疫苗问世 作用机制类似于基因疗法
2012-10-11 13:30 · Hebe一种治疗型宫颈癌疫苗已被研制出来，所以，它在测试的剂量范围内仅有轻微的副作用。其作用方式类似于基因疗法。
该研究团队的Mark Bagarazzi博士表示，这种名叫VGX-3100的疫苗专门针对的是由HPV16型和18型引起的癌症。
据本月10日的《科学.转化医学》，研发人员称，
Immunotherapy Against HPV16/18 Generates Potent TH1 and Cytotoxic Cellular Immune Responses.
Mark L. Bagarazzi, Jian Yan, Matthew P. Morrow, Xuefei Shen, R. Lamar Parker, Jessica C. Lee, Mary Giffear, Panyupa Pankhong, Amir S. Khan, Kate E. Broderick, Christine Knott, Feng Lin, Jean D. Boyer, Ruxandra Draghia-Akli, C. Jo White, J. Joseph Kim, David B. Weiner and Niranjan Y. Sardesai
Abstract：Despite the development of highly effective prophylactic vaccines against human papillomavirus (HPV) serotypes 16 and 18, prevention of cervical dysplasia and cancer in women infected with high-risk HPV serotypes remains an unmet medical need. We report encouraging phase 1 safety, tolerability, and immunogenicity results for a therapeutic HPV16/18 candidate vaccine, VGX-3100, delivered by in vivo electroporation (EP). Eighteen women previously treated for cervical intraepithelial neoplasia grade 2 or 3 (CIN2/3) received a three-dose (intramuscular) regimen of highly engineered plasmid DNA encoding HPV16 and HPV18 E6/E7 antigens followed by EP in a dose escalation study (0.3, 1, and 3 mg per plasmid). Immunization was well tolerated with reports of mild injection site reactions and no study-related serious or grade 3 and 4 adverse events.
文献链接：Immunotherapy Against HPV16/18 Generates Potent TH1 and Cytotoxic Cellular Immune Responses.
也就能有效降低宫颈癌的发病率。
与传统的疫苗不同，